OBIO marks $704m funding milestone for Canadian health tech ventures
The initiative is designed to help post-seed health science enterprises secure investment, form corporate partnerships.
Drug Development
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
AstraZeneca to invest $2bn in Summit for ADC combination therapies
Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma
Mirum and Incyte’s Atebrioz approved for FOP in US
Amberstone and Henlius agree to develop solid-tumour T-cell engagers
FDA approves Lilly’s Onswik for type 2 diabetes in adults
Genialis and Inventia to enhance pancreatic cancer treatment testing
